• Clene, a late clinical-stage biopharmaceutical company, creates clean-surfaced, catalytically active nanocrystals that directly modulate biological systems, including the central nervous system, by improving mitochondrial health
• The company’s lead investigational candidate, CNM-Au8(R), is currently in development as a disease-modifying treatment for people living with specific types of neurodegenerative disorders (“ND”), namely amyotrophic lateral sclerosis (“ALS”), Parkinson’s Disease, and multiple sclerosis (“MS”)
• Neurodegenerative disorders are characterized by neurodegeneration – the progressive loss of neuron structure, neuronal functions, and finally, the neurons themselves
• Nanotherapeutics are in development to stop or reverse neurodegeneration using novel approaches to address the mitochondrial deficits and bioenergetic crises common to these neurodegenerative diseases

Also known simply as nerve cells, neurons are central to most – if not all – of the body’s normal functions, from breathing and talking to eating, thinking, and walking (https://ibn.fm/zWMUR). They support these activities by sending and receiving information between the brain and muscles, and are also responsible for receiving sensory input from the external environment and relaying that information to the brain.

As crucial as neurons are, they are not immortal. Like all other cells in the body, nerve cells undergo apoptosis, which is the programmed process by which body cells die. Apoptosis helps remove surplus, aged, damaged, or unwanted cells. However, in some cases, apoptosis becomes dysregulated, leading…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN